Nordic Nanovector ASA said that Betalutin drug for the treatment of relapsed/refractory indolent non-Hodgkin lymphoma and follicular lymphoma demonstrated statistically significant results in ongoing phase 1/2 clinical study.
For relapsed/refractory indolent non-Hodgkin lymphoma, Betalutin as a single agent showed a reduction in tumor size in 90% of the patients. The drug demonstrated an overall response rate of 60% and a complete response rate of 24% in all evaluable patients.
Patients with follicular lymphoma were divided into two arms: the first arm demonstrated a 68% overall response rate and a 28% complete response, while the second arm had a 50% overall response rate and a 25% complete response.
The drug was highly active in patients with third stage follicular lymphoma who have received prior therapies and a 66% overall response rate and a 25% complete response was recorded.
The drug showed no safety concerns and was well-tolerated.
